EAM Global Investors’s Atara Biotherapeutics ATRA Stock Holding History

EAM Global Investors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,798	Closed	-$1.37M	–	143
2020 Q4	$1.37M	Buy	+2,798	New	+$1.29M	0.37%	119

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EAM Global Investors's ATRA Position: Q1 2021 in Review

EAM Global Investors sold out of Atara Biotherapeutics (ATRA) in Q1 2021, closing a stake of 2,798 shares — an estimated $1.37M sold.

EAM Global Investors first reported a position in ATRA in Q4 2020 and held it in 1 quarter. The position peaked at $1.37M in Q4 2020. 151 funds tracked by Wall St. Rank hold ATRA as of Q1 2021.

EAM Global Investors reported no remaining Atara Biotherapeutics position as of Q1 2021 after selling out during the quarter.
EAM Global Investors sold 2,798 Atara Biotherapeutics shares in Q1 2021, an estimated $1.37M.
EAM Global Investors first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 1 quarter.
EAM Global Investors's Atara Biotherapeutics position peaked at $1.37M in Q4 2020.
151 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2021.

Based on EAM Global Investors's 13F filing for Q1 2021, filed 11 May 2021.